Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

22.74
+0.91004.17%
Pre-market: 22.00-0.7400-3.25%08:24 EDT
Volume:821.16K
Turnover:18.66M
Market Cap:2.82B
PE:-179.25
High:23.00
Open:22.03
Low:21.95
Close:21.83
52wk High:31.77
52wk Low:11.86
Shares:124.03M
Float Shares:88.24M
Volume Ratio:0.43
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1269
EPS(LYR):-0.1269
ROE:-9.30%
ROA:-1.95%
PB:14.89
PE(LYR):-179.25

Loading ...

Arcutis Biotherapeutics, Inc. : H.c. Wainwright Raises Target Price to $34 From $30

THOMSON REUTERS
·
Feb 26

Arcutis Biotherapeutics Inc : TD Cowen Raises Target Price to $35 From $30

THOMSON REUTERS
·
Feb 26

Stock Track | Arcutis Biotherapeutics Soars 5.52% After-Hours on Strong Q4 Earnings Beat and Raised 2026 Guidance

Stock Track
·
Feb 26

Stock Track | Arcutis Biotherapeutics Soars 5.07% After-Hours on Strong Q4 Earnings Beat and Raised 2026 Guidance

Stock Track
·
Feb 26

Arcutis Biotherapeutics files automatic mixed securities shelf

TIPRANKS
·
Feb 26

BRIEF-Arcutis Biotherapeutics Inc Files For Mixed Shelf

Reuters
·
Feb 26

BRIEF-Arcutis Announces Fourth Quarter And Full Year 2025 Financial Results

Reuters
·
Feb 26

Arcutis Biotherapeutics Inc Files for Mixed Shelf; Size Not Disclosed- SEC Filing

THOMSON REUTERS
·
Feb 26

Arcutis Q4 revenue rises 84% on ZORYVE sales, raises FY guidance

Reuters
·
Feb 26

Arcutis Biotherapeutics Q4 EPS $0.13 Beats $0.10 Estimate, Sales $129.503M Beat $113.055M Estimate

Benzinga
·
Feb 26

Arcutis posts FY 2025 ZORYVE net product revenue of USD 372.1 million up 123%

Reuters
·
Feb 26

Arcutis Biotherapeutics Inc - Raises 2026 Sales Guidance to $480-$495 Mln

THOMSON REUTERS
·
Feb 26

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

THOMSON REUTERS
·
Feb 26

U.S. Earnings Preview: After Market Close Feb. 25

Dow Jones
·
Feb 26

Arcutis announces Max Homa joins ‘Free to Be Me’ campaign

TIPRANKS
·
Feb 24

Arcutis Biotherapeutics Grants 94,000 Restricted Stock Units to New Employees

Reuters
·
Feb 06

Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Feb 06

Director Howard G. Welgus Reports Sale of Arcutis Biotherapeutics Common Shares

Reuters
·
Feb 05

Arcutis Biotherapeutics Reports Positive Phase 2 Results for ZORYVE Cream in Infants with Atopic Dermatitis

Reuters
·
Feb 02

Arcutis Biotherapeutics Inc - Plans to Submit Snda for Zoryve Cream in Q2 2026

THOMSON REUTERS
·
Feb 02